The Drugs Are Losing: Inside America's Accelerating Crisis of Antibiotic-Resistant Infections

The Centers for Disease Control and Prevention reported in early 2026 that infections from NDM-CRE — a class of bacteria resistant to nearly all approved antibiotics — rose more than 460% between 2019 and 2023 [1]. The finding landed alongside broader CDC data showing that six categories of hospital-acquired resistant infections remain above pre-pandemic baselines [2]. These are not projections. They are body counts that have been climbing for years, through a pandemic that accelerated the problem, within a healthcare system that lacks the drugs, the funding, and in many cases the political will to reverse the trend.

The Numbers: Where the Crisis Stands

The CDC's landmark 2019 Antibiotic Resistance Threats Report estimated that more than 2.8 million antimicrobial-resistant infections occurred annually in the United States, killing approximately 35,900 people [3]. When Clostridioides difficile — a bacterium closely linked to antibiotic overuse — was included, the toll exceeded 3 million infections and 48,000 deaths [3].

Source: CDC Antimicrobial Resistance Reports

Data as of Jul 1, 2024CSV

Those figures represented a snapshot taken before COVID-19. The CDC's 2022 special report on the pandemic's impact found that during the first year of the crisis alone, more than 29,400 people died from antimicrobial-resistant infections commonly associated with healthcare settings, with nearly 40% of those infections acquired in hospitals [4]. The agency concluded bluntly that the pandemic had "set back" years of progress [4].

The most recent data, covering 2021–2022, confirmed that the spike was not transient. Six bacterial antimicrobial-resistant hospital-onset infections increased by a combined 20% during COVID-19 compared to pre-pandemic levels, peaking in 2021 and remaining elevated through 2022 [2]. MRSA was the sole pathogen whose hospital-onset infection rates returned to 2019 levels [2]. Every other tracked threat — including carbapenem-resistant Acinetobacter, ESBL-producing Enterobacterales, vancomycin-resistant Enterococcus, and multidrug-resistant Pseudomonas aeruginosa — stayed above its pre-pandemic baseline [2].

The Pathogens Driving the Warning

The CDC's most recent alarm centers on NDM-CRE, or New Delhi metallo-β-lactamase-producing carbapenem-resistant Enterobacteriaceae. These bacteria produce an enzyme that breaks down carbapenems — a class of antibiotics typically reserved as a last resort when other treatments fail [1]. NDM-CRE can cause pneumonia, bloodstream infections, urinary tract infections, and wound infections, and many clinical laboratories still lack diagnostic tools to reliably identify these strains, leading to potential misdiagnosis and delayed treatment [1].

But NDM-CRE is only the most alarming entry in a growing list. Candida auris, a fungus often resistant to multiple antifungal medications, saw reported clinical cases increase nearly fivefold from 2019 to 2022 [2]. Drug-resistant Shigella — which causes severe, sometimes bloody diarrhea — went from essentially zero cases of extreme drug resistance in 2011 to 8.5% of all infections by 2023, prompting a separate CDC advisory [5]. And drug-resistant Neisseria gonorrhoeae continues to develop resistance to frontline treatments: between 2022 and 2024, resistance to ceftriaxone rose from 0.8% to 5%, and resistance to cefixime climbed from 1.7% to 11% [6].

Source: Annals of Internal Medicine / CDC

Data as of Jul 1, 2024CSV

How COVID-19 Made It Worse

The pandemic's impact on antibiotic resistance was both direct and systemic. Hospital stays lengthened, infection-control practices were strained, and antibiotic prescribing surged — often empirically, in COVID-19 patients who did not have bacterial co-infections [4][7].

A retrospective cohort study of 243 U.S. hospitals found that hospital-onset antimicrobial-resistant infections increased from 28.9 to 38.0 per 10,000 hospitalizations between 2019 and 2021 [8]. The study identified a strong association between antibiotic exposure and hospital-onset resistant infections, suggesting the surge was not merely a reporting artifact [8].

Antifungal-resistant threats rose in parallel: Candida auris infections increased 60% overall in 2020, with other Candida species showing a 26% increase in hospital settings [4]. The CDC's special report attributed these increases to longer patient stays, overcrowded wards, staffing shortages, and the diversion of infection-prevention resources to COVID-19 response [4].

Some of those gains have since receded. By 2022, hospital-onset AMR infection rates had declined from their 2021 peak but had not returned to pre-pandemic levels for most pathogens [2]. The question facing epidemiologists is whether the post-pandemic trajectory represents a slow recovery or a permanently elevated baseline.

The US Compared to Peer Nations

Comparing antibiotic resistance responses across countries reveals both shared challenges and policy gaps. The United Kingdom has been the most aggressive in addressing market incentives. Following a pilot program that began in 2019, the UK's National Health Service now uses a subscription model — sometimes called the "Netflix model" — in which the government pays pharmaceutical companies a fixed annual fee for access to new antibiotics, regardless of volume used [9]. Maximum contract values have been doubled to £20 million per year, and the program has been expanded from England to the entire UK [9].

The European Union has allocated €50 million in direct grants for antimicrobial resistance work and launched HERA Invest in 2023 with €100 million to support clinical trials at small and mid-sized companies [10]. Australia mandated antimicrobial stewardship as a hospital accreditation standard in 2011, updated in 2015, creating a structural incentive for compliance that the U.S. lacks at the federal level [11].

In the United States, the proposed PASTEUR Act would create a subscription-style system modeled on the UK approach, authorizing up to $6 billion for contracts with manufacturers of qualifying new antibiotics, with individual contracts ranging from $750 million to $3 billion over 5–10 years [12]. The bill has been reintroduced in Congress but has not passed [12]. Meanwhile, U.S. federal funding for antibiotic resistance research was doubled under the Obama administration's 2015 national action plan [13], but sustained increases have not kept pace with the scale of the threat.

Farm Antibiotics: A Contested Contribution

Globally, animal agriculture accounts for a substantial share of total antibiotic consumption. In the United States, the FDA's 2017 Veterinary Feed Directive (VFD) banned the use of medically important antibiotics for growth promotion in livestock and required veterinary oversight for therapeutic use in feed and water [14].

The policy showed early results. FDA summary reports indicated that sales of medically important antibiotics for livestock decreased 14% in 2016, the last year before full implementation [14]. Federal statistics suggest continued declines after 2017 [15]. However, the VFD's impact on actual resistance rates in human infections remains difficult to isolate. The connection between agricultural antibiotic use and clinical resistance in humans is well-established in principle — resistant bacteria can transfer from animals to humans through food, water, and environmental contamination — but quantifying the contribution relative to clinical overuse is methodologically challenging [15].

Industry groups, including the American Veterinary Medical Association, have argued that the VFD struck an appropriate balance, putting antibiotic decisions in the hands of trained veterinarians while preserving the ability to treat sick animals [14]. Critics counter that "therapeutic use" exemptions remain broad enough to allow routine low-dose administration to entire herds, functionally replicating the selective pressure of growth promotion under a different label [15].

A Pipeline Running Dry

The most structurally troubling dimension of the crisis is the collapse of antibiotic development. Between 1980 and 1999, the FDA approved 52 systemic antibacterial new molecular entities. Between 2000 and 2024, it approved 28 — with only four approvals from 2020 through 2024 [16][17].

Source: CIDRAP / Nature Reviews

Data as of Jan 1, 2025CSV

The decline reflects a market failure specific to antibiotics. Unlike cancer drugs or chronic-disease medications prescribed continuously, effective new antibiotics are intentionally held in reserve and prescribed sparingly — to delay resistance. This means that even a successful antibiotic generates far less revenue than drugs in other therapeutic areas. Venture capital invested $7 billion in oncology companies in 2020 alone, a 900% increase over 2011. Investment in antibiotic companies in the same year: $160 million, below levels from a decade earlier [17].

The consequences for small companies — which now discover 81% of pipeline antibiotics — have been severe. Of 12 antibiotic-focused companies that went public in the past decade, only five remain active [17]. Achaogen, which developed the FDA-approved antibiotic plazomicin for complicated urinary tract infections, declared bankruptcy within a year of receiving approval [17].

The current global pipeline contains roughly 90 antibiotics in clinical development, down from 97 in 2023 [18]. Only 15 are classified as innovative, and just five target WHO "critical priority" pathogens [18]. Phase 1 clinical trial initiations fell 46% between 2016–2020 compared to the previous five-year period [17].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Academic interest, by contrast, has surged: research publications on antimicrobial resistance grew from approximately 12,000 in 2011 to over 97,000 in 2025 [19]. The gap between scientific understanding and commercial drug development continues to widen.

Who Bears the Burden

Drug-resistant infections do not distribute evenly across the population. Black patients have higher rates of both hospital-onset and community-acquired MRSA infections than white patients, a disparity researchers have linked to reduced access to affordable medical care, higher rates of poverty and crowded living conditions, and greater prevalence of chronic comorbidities [20][21]. A study in Clinical Infectious Diseases found that the racial disparity in invasive community-associated MRSA rates was largely explained by socioeconomic factors rather than biological differences [21].

Geography compounds the problem. Research on "pharmacy deserts" has found poorer access to pharmacies — and therefore to timely antibiotic treatment — in predominantly Black and Hispanic neighborhoods [22]. People who are uninsured, undocumented, or living in crowded urban areas face elevated risk regardless of race or ethnicity [20].

A 2014–2015 CDC study found that white persons reported roughly twice as many antimicrobial prescription fills per capita as persons of other racial and ethnic groups [23]. This disparity cuts in two directions: it may reflect undertreatment of infections in minority populations, but it also means white patients face greater selective pressure for resistance from higher antibiotic consumption. Neither outcome is desirable.

The CDC's public warnings have generally been framed as broad population-level alerts rather than targeted communications aimed at the highest-risk groups. Public health researchers have questioned whether this approach effectively reaches the communities where interventions are most urgently needed, or whether it defaults to messaging that reaches primarily those who already have access to healthcare and information [20].

The Awareness Paradox

There is an underexplored tension in public health communication about antibiotic resistance. Awareness campaigns are designed to change behavior — but not all behavioral changes run in the intended direction.

Physicians report significant pressure from patients who expect antibiotics even when the illness does not warrant them [24]. A 2021 study published in Social Science & Medicine found that patient expectations for a tangible prescription, particularly after spending time and money on a medical visit, remain a powerful driver of unnecessary prescribing [24]. In private clinic settings, physicians described feeling obligated to provide "value" through a prescription, even when aware the antibiotic was not medically indicated [25].

Patient satisfaction scores compound the problem. Physicians have expressed concern that refusing to prescribe antibiotics results in negative reviews, creating a perverse incentive within healthcare systems that tie compensation or performance evaluations to patient feedback [25].

Research on awareness campaigns has found mixed results. A systematic review concluded that most global AMR campaigns — including World Antimicrobial Awareness Week — have not produced significant changes in public behavior [26]. More effective campaigns combined mass-media outreach with community-level messaging in pharmacies and clinics [26]. A CIDRAP analysis found that comparing antibiotic resistance to COVID-19 as a framing device failed to reduce antibiotic-seeking behavior among surveyed patients [27].

The question for journalists and public health agencies is whether high-profile threat warnings — of the kind the CDC issued in April 2026 — risk triggering anxiety-driven doctor visits that end with unnecessary prescriptions, incrementally worsening the problem they intend to solve. The evidence does not support suppressing information, but it does suggest that how warnings are framed matters as much as whether they are issued.

What Comes Next

The CDC has announced that later in 2026 it will release updated estimates for at least 19 antimicrobial resistance threats in a new electronic format, providing the most comprehensive picture of the U.S. burden since the 2019 report [2]. Whether that data shows continued post-pandemic recovery or renewed acceleration will shape policy debates for years.

In the meantime, the structural problems remain unresolved. The antibiotic pipeline is thin and commercially fragile. The PASTEUR Act, which would create UK-style subscription incentives, awaits congressional action [12]. Agricultural antibiotic use has declined but its contribution to clinical resistance remains contested [15]. And the populations most vulnerable to drug-resistant infections — low-income, minority, and uninsured communities — remain the least likely to be reached by either new treatments or targeted public health interventions [20].

The bacteria are not waiting for policy consensus.